A Swiss Amish community in Indiana has been the focus of ongoing studies led by Dr. Douglas Vaughan, chair of the Department of Medicine at Northwestern. Many members of this Amish community have a gene mutation that appears to protect against biological aging in a variety of ways.  A new experimental drug that effectively lowers the level of the protein associated with this mutation is now being tested as a treatment for people with COVID-19, in a phase 2 clinical trial at Northwestern.